Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma

Kieron Dunleavy, Stefania Pittaluga, Margaret Shovlin, Mark Roschewski, Catherine Lai, Seth M Steinberg, Elaine S Jaffe, Wyndham H Wilson, Kieron Dunleavy, Stefania Pittaluga, Margaret Shovlin, Mark Roschewski, Catherine Lai, Seth M Steinberg, Elaine S Jaffe, Wyndham H Wilson

No abstract available

Keywords: EPOCH; dose-adjusted; phase II; systemic aplastic large cell lymphoma.

Figures

Figure 1.

Outcome of 24 patients (15 ALK positive and 9 ALK negative) following DA-EPOCH. (A) Event-free survival (EFS) of ALK positive versus ALK negative patients. (B) Overall survival of ALK positive versus negative cases.